The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Werewolf Therapeutics
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.
 
Justin C Moser
Honoraria - Caris Life Sciences; Daiichi Sankyo/Lilly; TGen
Consulting or Advisory Role - Adagene; Amunix; Boxer Capitol; Bristol Myers Squibb Foundation; Genome Insight; Imaging Endpoints; Incyte; IQvia; Novotech; Oberland Capital; Red Arrow Therapeutics; Thirona Biosciences; Werewolf Therapeutics (Inst)
Speakers' Bureau - Caris Life Sciences; Castle Biosciences; Immunocore
Research Funding - Adaptimmune (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); BioEclipse Therapeutics (Inst); Fate Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); IDEAYA Biosciences (Inst); ImmuneSensor Therapeutics (Inst); Iovance Biotherapeutics (Inst); Istari Oncology (Inst); Nektar (Inst); Novocure (Inst); Repertoire Immune Medicines (Inst); Rubius Therapeutics (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Storm Therapeutics (Inst); Synthorx (Inst); T-Scan Therapeutics (Inst); Trishula Therapeutics (Inst); University of Arizona (Inst); Werewolf Therapeutics (Inst); Y-mAbs Therapeutics (Inst)
Other Relationship - Caris Life Sciences
 
Mateusz Opyrchal
Stock and Other Ownership Interests - crispr therapeutics
Consulting or Advisory Role - AstraZeneca
Research Funding - Alphageneron; Bayer; Pfizer
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Syneos Health
 
Brendan D. Curti
Honoraria - Clinigen Group; Sanofi
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
 
Igor Puzanov
Stock and Other Ownership Interests - Compugen; IDEAYA Biosciences; IDEAYA Biosciences (I)
Consulting or Advisory Role - Iovance Biotherapeutics; Nouscom
Research Funding - NIH/NCI (Inst)
 
Jeffrey A. Sosman
Honoraria - Apexigen; Aveo; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Iovance Biotherapeutics; Jazz Pharmaceuticals
Research Funding - Werewolf Pharma (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Kristin Morris
Employment - Werewolf Therapeutics
Stock and Other Ownership Interests - Werewolf Therapeutics
Patents, Royalties, Other Intellectual Property - On patent application related to Werewolf Therapeutics intellectual property (Inst)
Travel, Accommodations, Expenses - Werewolf Therapeutics
 
Christopher J. Nirschl
No Relationships to Disclose
 
Saero Park
Employment - Werewolf Therapeutics
 
Marissa Bruno
No Relationships to Disclose
 
Paul Windt
Employment - Bicara Therapeutics (I); Werewolf Therapeutics
Stock and Other Ownership Interests - Novartis; Regeneron; Werewolf Therapeutics
 
Kulandayan K. Subramanian
Employment - Daiichi Sankyo; United Health Group (I); Werewolf Therapeutics
Stock and Other Ownership Interests - Avidity Biosciences; CureVac; CureVac; Dynavax Technologies; Gilead Sciences; Intellia Therapeutics; MindMed; Moderna Therapeutics; Novavax; UnitedHealthcare (I); Werewolf Therapeutics
Patents, Royalties, Other Intellectual Property - Patent 059034-US-PCT Dosage regimes for anti-CD73 and anti-ENTPD2 antibodies and uses of thereof; Patent PCT/US23/78580 NKG2D fusion protein cancer therapy
 
Oliver Schönborn-Kellenberger
Employment - Cogitars
 
Sameer Chopra
Employment - Takeda; Werewolf Therapeutics
Stock and Other Ownership Interests - Werewolf Therapeutics
 
Randi Isaacs
Employment - Werewolf Therapeutics
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Werewolf Therapeutics
Consulting or Advisory Role - C4 Therapeutics; Hookipa Biotech
Patents, Royalties, Other Intellectual Property - I am listed on several patents from Werewolf Therapeutics around the clinical use of the INDUKINE molecules, as well as from my previous employment with Novartis Pharmaceuticals involving CAR-T therapy